Mats Jerkeman

10.5k total citations · 1 hit paper
214 papers, 4.9k citations indexed

About

Mats Jerkeman is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Mats Jerkeman has authored 214 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 177 papers in Pathology and Forensic Medicine, 96 papers in Oncology and 70 papers in Genetics. Recurrent topics in Mats Jerkeman's work include Lymphoma Diagnosis and Treatment (177 papers), Chronic Lymphocytic Leukemia Research (65 papers) and Viral-associated cancers and disorders (51 papers). Mats Jerkeman is often cited by papers focused on Lymphoma Diagnosis and Treatment (177 papers), Chronic Lymphocytic Leukemia Research (65 papers) and Viral-associated cancers and disorders (51 papers). Mats Jerkeman collaborates with scholars based in Sweden, Denmark and Norway. Mats Jerkeman's co-authors include Thomas Relander, Fredrik Ellin, Sara Ek, Michael Dictor, Simon Rule, Arne Kolstad, Sirpa Leppä, Marco Ladetto, M. Dreyling and Peter de Nully Brown and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Mats Jerkeman

200 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017 412 citations Olivier Hermine, Mats Jerkeman et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Mats Jerkeman

Since Specialization

Citations

This map shows the geographic impact of Mats Jerkeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mats Jerkeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mats Jerkeman more than expected).

Fields of papers citing papers by Mats Jerkeman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mats Jerkeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mats Jerkeman. The network helps show where Mats Jerkeman may publish in the future.

Co-authorship network of co-authors of Mats Jerkeman

This figure shows the co-authorship network connecting the top 25 collaborators of Mats Jerkeman. A scholar is included among the top collaborators of Mats Jerkeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mats Jerkeman. Mats Jerkeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma 2025 ·Blood Advances ·Leo Meriranta, (unknown), (unknown), Arne Kolstad, Martin Hutchings, Carsten Utoft Niemann, Tarec Christoffer El‐Galaly, Jon Riise, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius, Sirpa Leppä, Mats Jerkeman	1
2	Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden 2025 ·Leukemia ·Mats Jerkeman, Karin Mellgren, Kristina Sonnevi, (unknown), (unknown), (unknown), (unknown), Jacek Toporski, Hans Hagberg, (unknown), Gunilla Enblad	0
3	Infections in patients with mantle cell lymphoma 2024 ·HemaSphere ·Kossi Abalo, Sara Ekberg, Therése Andersson, (unknown), (unknown), Karin E. Smedby, Mats Jerkeman, Ingrid Glimelius	4
4	Effectiveness of R‐CHOP versus R‐CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study 2024 ·European Journal Of Haematology ·(unknown), Lasse Jakobsen, Sandra Eloranta, Karin E. Smedby, Robert Schou Pedersen, Judit Jørgensen, Michael Roost Clausen, Peter de Nully Brown, Anne Ortved Gang, (unknown), Thomas Stauffer Larsen, Mats Jerkeman, Tarec Christoffer El‐Galaly	2
5	Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of Patients 2024 ·Cancers ·(unknown), (unknown), (unknown), (unknown), Lina Olsson, Paul Theodor Pyl, Louella Vasquez, Anna Porwit, Anna Sandström Gerdtsson, Mats Jerkeman, Sara Ek	2
6	MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and <i>TP53</i>/p53 – a Nordic Lymphoma Group study 2023 ·Haematologica ·(unknown), Peter Hollander, (unknown), (unknown), (unknown), Darshan Kumar, Christian H. Geisler, Kirsten Grønbæk, Christian Winther Eskelund, Riikka Räty, Arne Kolstad, Christer Sundström, Ingrid Glimelius, Anna Porwit, Mats Jerkeman, Sara Ek	5
7	ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia 2023 ·Annals of Oncology ·D. Hoelzer, Renato Bassan, Nicolas Boissel, Claire Roddie, Josep‐María Ribera, Mats Jerkeman	11
8	Secondary malignancies among mantle cell lymphoma patients 2023 ·European Journal of Cancer ·Kossi Abalo, Karin E. Smedby, Sara Ekberg, Sandra Eloranta, (unknown), (unknown), Mats Jerkeman, Ingrid Glimelius	5
9	Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients 2022 ·British Journal of Haematology ·(unknown), Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Tarec Christoffer El‐Galaly, Birgitta Sander, Kristina Sonnevi, Per‐Ola Andersson, Mats Jerkeman, Karin E. Smedby	20
10	Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission 2022 ·British Journal of Cancer ·Sara Ekberg, Michael J. Crowther, (unknown), Mats Jerkeman, Karin E. Smedby, Sandra Eloranta	2
11	Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation 2022 ·Blood Advances ·Sara Ekberg, Karin E. Smedby, (unknown), Mats Jerkeman, Caroline E. Weibull, Ingrid Glimelius	5
12	Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma 2021 ·Blood ·Leo Meriranta, Amjad Alkodsi, Annika Pasanen, Maija Lepistö, (unknown), Yngvild Nuvin Blaker, Judit Jørgensen, Marja‐Liisa Karjalainen‐Lindsberg, (unknown), (unknown), Matias Autio, Magnus Björkholm, Mats Jerkeman, Øystein Fluge, Peter de Nully Brown, Sirkku Jyrkkiö, Harald Holte, Esa Pitkänen, Pekka Ellonen, Sirpa Leppä	71
13	Detecting deviations from the efficacy and safety results of single‐arm trials using real‐world data: The case of a CAR‐T cell therapy in B‐cell lymphoma 2021 ·Pharmacoepidemiology and Drug Safety ·Lasse Hjort Jakobsen, Torbjörn Callréus, Maurizio Sessa, Mats Jerkeman, Morten Andersen, Tarec Christoffer El‐Galaly	2
14	Myocardial infarction in diffuse large B‐cell lymphoma patients – a population‐based matched cohort study 2021 ·Journal of Internal Medicine ·Sara Ekberg, (unknown), Tomas Jernberg, Karolina Szummer, Per‐Ola Andersson, Mats Jerkeman, Karin E. Smedby, Sandra Eloranta	10
15	p53 is associated with high‐risk and pinpointsTP53missense mutations in mantle cell lymphoma 2020 ·British Journal of Haematology ·(unknown), (unknown), C. Freiburghaus, Christian Winther Eskelund, Christian H. Geisler, Riikka Räty, Arne Kolstad, Christer Sundström, Ingrid Glimelius, Kirsten Grønbæk, (unknown), Anna Porwit, Mats Jerkeman, Sara Ek	33
16	Trends in the prevalence, incidence and survival of non‐Hodgkin lymphoma subtypes during the 21st century – a Swedish lymphoma register study 2020 ·British Journal of Haematology ·Sara Ekberg, Karin E. Smedby, Ingrid Glimelius, Herman Nilsson‐Ehle, (unknown), Catharina Lewerin, Mats Jerkeman, Sandra Eloranta	21
17	Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases 2019 ·Pharmaceutical Medicine ·Torbjörn Callréus, Tarec Christoffer El‐Galaly, Mats Jerkeman, Peter de Nully Brown, Morten Andersen	2
18	TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy 2017 ·Blood ·Christian Winther Eskelund, Christina Dahl, Jakob Werner Hansen, Maj Westman, Arne Kolstad, Lone Bredo Pedersen, Carmen P. Montano‐Almendras, Simon Husby, C. Freiburghaus, Sara Ek, Anja Pedersen, Carsten Utoft Niemann, Riikka Räty, Peter de Nully Brown, Christian H. Geisler, Mette Klarskov Andersen, Per Guldberg, Mats Jerkeman, Kirsten Grønbæk	242
19	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 2017 ·Leukemia & lymphoma ·Martin Dreyling, Igor Aurer, Sergio Cortelazzo, Olivier Hermine, Georg Heß, Mats Jerkeman, Steven Le Gouill, Vincent Ribrag, Marek Trněný, (unknown), Jan Walewski, Francesco Zaja, Pier Luigi Zinzani	18
20	Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma 2016 ·Blood ·(unknown), Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, J. Sundberg, Lone Bredo Pedersen, Elisabeth Ralfkiær, Marja-Liisa Karjalainen-Lindsberg, Christer Sundström, Mats Ehinger, Christian H. Geisler, Mats Jerkeman	62

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact